Benedict Kusi Ampofo

Dr. Benedict Kusi Ampofo

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2026 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
POPriscilla Abrafi Opare-Addo
Priscilla Abrafi Opare-Addo
FSFred S. Sarfo
Fred S. Sarfo
COChris Oppong
Chris Oppong
SASheila Adamu
Sheila Adamu
IYIshaak Ahmed Yussif
Ishaak Ahmed Yussif
JBJosé Biller
José Biller
Despite bearing the brunt of the global burden of post-stroke disability, cost-effective acute treatments such as stroke thrombolysis remain significantly underutilized in Low- and Middle-Income Countries. Pragmatic implementation strategies tailored to the local contexts could bridge the gap between evidence and practice and potentially improve access in these regions. To assess the effectiveness of a multicomponent implementation strategy in improving access and timeliness of stroke thrombolysis in a Ghanaian tertiary hospital. We conducted a pre- and post-implementation analysis after rolling out a 3-pronged implementation strategy to improve the incorporation of stroke thrombolysis into routine stroke care at the Komfo Anokye Teaching Hospital. This strategy was guided by the Implementation Research Logic Model, targeting multiple contextual barriers in tandem across multiple stakeholders. It entailed a public awareness campaign, establishment of a multidisciplinary stroke team with code-driven stroke protocols, and cost mitigation strategies. The pre-implementation needs assessment was from November 2022 to April 2023, while the implementation phase was from February 2024 to August 2024. Compared to the pre-implementation phase, the thrombolysis eligibility rate rose from 7.9% to 9.5%, p=0.581, while the stroke thrombolysis rate increased from 0.83% (2 out of 242) to 4.03% (14 out of 347) during the implementation phase, p=0.020. Regarding timeliness, 13.5% arrived within 3 hours of stroke onset in the implementation phase compared to 5.6% during the pre-implementation period, p=0.000. The average door-to-needle time was 1 hour, 48 minutes, which was faster compared to 2 hours, 37 minutes in the pre-implementation phase, p=0.000. Access to intravenous thrombolysis was equitably distributed irrespective of the patient's socio-demographics. Our findings highlight the potential of contextually tailored implementation strategies, embedded in a structured implementation framework, to improve access to stroke thrombolysis even in resource-constrained settings. Our findings provide a template for the implementation of stroke services in the sub-region.

17 February 2026 in Clinical Case Reports
Verified
Journal Article
Open access
BABenedict Kusi Ampofo
Benedict Kusi Ampofo
AAAugustine Kwame Afful
Augustine Kwame Afful
PSPriscilla Konadu Sakyi
Priscilla Konadu Sakyi
JAJusticia Amisah
Justicia Amisah
MBMichael Bruce‐Smith
Michael Bruce‐Smith
KTKwasi Adjepong Twum
Kwasi Adjepong Twum
Venous thromboembolism is a recognized but often underdiagnosed complication of pediatric musculoskeletal infections, particularly in low‐resource settings where access to Doppler ultrasonography, magnetic resonance imaging, and computed tomography pulmonary angiography (CTPA) remains limited. We describe two previously healthy children who developed deep vein thrombosis with pulmonary embolism secondary to acute musculoskeletal infection. Both presented initially with fever, severe limb pain, and rapidly progressive swelling, followed by the onset of tachypnoea and respiratory compromise. Doppler ultrasonography confirmed lower‐limb deep vein thrombosis in both cases, while computed tomography pulmonary angiography in one child demonstrated bilateral pulmonary emboli with pulmonary infarction. In the second child, pulmonary embolism was diagnosed based on clinical deterioration and characteristic chest radiographic findings in the absence of available computed tomography. Both children were managed successfully with intravenous antibiotics, therapeutic anticoagulation, and surgical drainage where indicated, although one required mechanical ventilation in the pediatric intensive care unit. These cases highlight the diagnostic challenges of venous thromboembolism complicating musculoskeletal infection in resource‐limited settings and emphasize the importance of maintaining a high index of suspicion when limb swelling worsens or respiratory symptoms develop. Bedside Doppler ultrasonography and timely referral remain essential tools for reducing morbidity when advanced imaging is inaccessible.

21 January 2026 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
BABenedict Kusi Ampofo
Benedict Kusi Ampofo
FSFred Stephen Sarfo
Fred Stephen Sarfo
This version may be subject to change during the production process.


26 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LALambert Tetteh Appiah
Lambert Tetteh Appiah
FAFlorence Koryo Akumiah
Florence Koryo Akumiah
JIJacob Solomon Idan
Jacob Solomon Idan
GAGordon Manu Amponsah
Gordon Manu Amponsah
SGSolomon Gyabaah
Solomon Gyabaah
CACharles Agyemang
Charles Agyemang
Background: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like particle covalently bound to apolipoprotein(a) and encoded by the LPA gene. Elevated plasma levels of Lp(a) are a well-established, independent, and causal risk factor for cardiovascular disease. While the epidemiology of Lp(a) has been extensively mapped in non- African populations, the burden and distribution of Lp(a) in African populations remain under-characterized despite its unique genetic, phenotypic, ethnolinguistic and ancestral diversity. The primary objective was to synthesize existing literature to determine the prevalence and distribution of elevated Lp(a) levels in apparently healthy African individuals residing on the African continent. Methods: This systematic review included observational studies (cross-sectional, cohort, and case-control) involving apparently healthy adults (≥18 years) in Africa. The review systematically searched PubMed/MEDLINE, Embase, Scopus, African Journals Online, and Google Scholar without language or date restrictions to capture the full breadth of historical and contemporary data. Data were extracted using a standardized form capturing study characteristics, population demographics, assay methods and quantitative outcomes. Methodological quality was assessed using the Newcastle-Ottawa Scale. Results: A total of 17 studies met the inclusion criteria, representing populations from West Africa (Nigeria, Ghana) Central Africa (Cameroon), Southern Africa (South Africa, Zimbabwe), and North Africa (Morocco, Tunisia). Studies in Ghana reported prevalence rates of elevated Lp(a) (>30 mg/dL) between 30–61%. Lp(a) mean levels ranged from 12.7 mg/dL to 54.5 mg/dL depending on the cohort and assay used. Females exhibited higher Lp(a) levels than males across most African cohorts. Clinically, elevated Lp(a) was associated with hypertension, type 2 diabetes mellitus, ischemic stroke, myocardial infarction and anti-retroviral drug use. Conclusion: Elevated Lp(a) is a common, genetically determined trait in Africa rather than a rare dyslipidemia. Far from being a benign variant, it acts as a significant amplifier of cardiovascular risk, particularly in the presence of rising incident rates of hypertension and diabetes. Addressing this burden requires the adoption of standardized, isoform-independent assays and the development of population-specific risk thresholds to guide targeted preventive cardiovascular care.

10 February 2026 in International Health
Verified
Journal Article
Open access
BABenedict Kusi Ampofo
Benedict Kusi Ampofo
MAMarian Sapara Arthur
Marian Sapara Arthur
SGSolomon Gyabaah
Solomon Gyabaah